merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Lilly positions its vials as a safer option than compounded drugs for people who cannot afford its pens, as compounded drugs are subject to far less oversight than traditionally approved medications.</answer>

<question_number>2</question_number>
<answer>Lilly's vials will be made available only through LillyDirect, a telehealth platform that connects patients with providers who can prescribe obesity drugs, directly competing with telehealth companies offering compounded medications.</answer>

<question_number>3</question_number>
<answer>Compounded drugs are subject to far less oversight than traditionally approved medications, and health officials have repeatedly warned against taking compounded weight-loss drugs in particular.</answer>

<question_number>4</question_number>
<answer>Lilly is positioning its vials as a safer option than compounded drugs for people who cannot afford its pens, potentially regaining customers who are currently getting compounded tirzepatide.</answer>

<question_number>5</question_number>
<answer>The FDA will have to review the supply before taking tirzepatide off its shortage list, and when off the shortage list, there should be no space for mass compounders, which relates to Lilly's legal challenges against compounding pharmacies.</answer>

<question_number>6</question_number>
<answer>Lilly is able to offer "transparent pricing" for the vials in part because it can sell the drug directly, "removing third-party supply chain entities."</answer>

<question_number>7</question_number>
<answer>The drugs come with unique risks for older patients, including a loss of muscle mass that may make people over 65 more likely to suffer fractures or become frail, and Medicare has so far declined to cover medications strictly for weight loss.</answer>

<question_number>8</question_number>
<answer>Lilly is positioning its vials as a safer option than compounded drugs, which could influence safety perceptions of patients currently using compounded tirzepatide.</answer>

<question_number>9</question_number>
<answer>Tirzepatide is listed as "in shortage" by the FDA, which allows compounding pharmacies to legally produce alternative versions of the medication.</answer>

<question_number>10</question_number>
<answer>"We will get this market share back from you, even if it means lower pricing."</answer>